Health

Beating B-Cells for MS

Medication targets cells that fuel brain inflammation.

By Linda MarsaFeb 1, 2018 12:00 AM
DSC-E0218_18.jpg
Ocrelizumab is the first FDA-approved treatment for primary-progressive MS. | Genentech

Newsletter

Sign up for our email newsletter for the latest science news
 

More than 400,000 Americans are afflicted with multiple sclerosis, an autoimmune disease that disrupts the brain’s neural signals to the body. In March, the Food and Drug Administration approved the drug ocrelizumab to treat not only the milder form of MS, but also the primary-progressive form, for which there was no treatment until now.

In both types of MS, immune system cells attack and strip away myelin, the fatty protective sheathing that insulates nerve cells. This interferes with nerve signals, causing muscle weakness, lack of coordination, blurry vision, bowel and bladder problems and foggy thinking.

The new-to-market drug takes a novel approach. Whereas traditional MS medications target the immune system’s T-cells, ocrelizumab focuses on destroying the system’s B-cells, which fuel the brain inflammation that causes the disease to worsen.

During clinical trials, MRI scans showed that ocrelizumab reduces new brain inflammation in the milder relapse-remitting form, and slows deterioration in the progressive and most aggressive form. Along the way, the experiments have resulted in important information on how MS attacks the body, says Stephen Hauser, a neurologist at the University of California, San Francisco, whose lab spent decades determining the critical role B-cells play in the disease.

1 free article left
Want More? Get unlimited access for as low as $1.99/month

Already a subscriber?

Register or Log In

1 free articleSubscribe
Magazine Examples
Want more?

Keep reading for as low as $1.99!

Subscribe

Already a subscriber?

Register or Log In

More From Discover
Recommendations From Our Store
Shop Now
Stay Curious
Join
Our List

Sign up for our weekly science updates.

 
Subscribe
To The Magazine

Save up to 70% off the cover price when you subscribe to Discover magazine.

Copyright © 2021 Kalmbach Media Co.